325 related articles for article (PubMed ID: 26215403)
1. Thymoquinone enhances cisplatin-response through direct tumor effects in a syngeneic mouse model of ovarian cancer.
Wilson AJ; Saskowski J; Barham W; Yull F; Khabele D
J Ovarian Res; 2015 Jul; 8():46. PubMed ID: 26215403
[TBL] [Abstract][Full Text] [Related]
2. Microenvironmental effects limit efficacy of thymoquinone treatment in a mouse model of ovarian cancer.
Wilson AJ; Saskowski J; Barham W; Khabele D; Yull F
Mol Cancer; 2015 Nov; 14():192. PubMed ID: 26552746
[TBL] [Abstract][Full Text] [Related]
3. Tracking NF-κB activity in tumor cells during ovarian cancer progression in a syngeneic mouse model.
Wilson AJ; Barham W; Saskowski J; Tikhomirov O; Chen L; Lee HJ; Yull F; Khabele D
J Ovarian Res; 2013 Sep; 6(1):63. PubMed ID: 24020521
[TBL] [Abstract][Full Text] [Related]
4. The Effect of Thymoquinone on Apoptosis of SK-OV-3 Ovarian Cancer Cell by Regulation of Bcl-2 and Bax.
Liu X; Dong J; Cai W; Pan Y; Li R; Li B
Int J Gynecol Cancer; 2017 Oct; 27(8):1596-1601. PubMed ID: 28692636
[TBL] [Abstract][Full Text] [Related]
5. Thymoquinone and cisplatin as a therapeutic combination in lung cancer: In vitro and in vivo.
Jafri SH; Glass J; Shi R; Zhang S; Prince M; Kleiner-Hancock H
J Exp Clin Cancer Res; 2010 Jul; 29(1):87. PubMed ID: 20594324
[TBL] [Abstract][Full Text] [Related]
6. Thymoquinone inhibits growth of human medulloblastoma cells by inducing oxidative stress and caspase-dependent apoptosis while suppressing NF-κB signaling and IL-8 expression.
Ashour AE; Ahmed AF; Kumar A; Zoheir KM; Aboul-Soud MA; Ahmad SF; Attia SM; Abd-Allah AR; Cheryan VT; Rishi AK
Mol Cell Biochem; 2016 May; 416(1-2):141-55. PubMed ID: 27084536
[TBL] [Abstract][Full Text] [Related]
7. Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF-κB regulated gene products in multiple myeloma xenograft mouse model.
Siveen KS; Mustafa N; Li F; Kannaiyan R; Ahn KS; Kumar AP; Chng WJ; Sethi G
Oncotarget; 2014 Feb; 5(3):634-48. PubMed ID: 24504138
[TBL] [Abstract][Full Text] [Related]
8. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
[TBL] [Abstract][Full Text] [Related]
9. Caveolin-1 mediates chemoresistance in cisplatin-resistant ovarian cancer cells by targeting apoptosis through the Notch-1/Akt/NF-κB pathway.
Zou W; Ma X; Hua W; Chen B; Cai G
Oncol Rep; 2015 Dec; 34(6):3256-63. PubMed ID: 26503358
[TBL] [Abstract][Full Text] [Related]
10. The oncogenic Golgi phosphoprotein 3 like overexpression is associated with cisplatin resistance in ovarian carcinoma and activating the NF-κB signaling pathway.
He S; Niu G; Shang J; Deng Y; Wan Z; Zhang C; You Z; Shen H
J Exp Clin Cancer Res; 2017 Oct; 36(1):137. PubMed ID: 28978336
[TBL] [Abstract][Full Text] [Related]
11. The combination of thymoquinone and paclitaxel shows anti-tumor activity through the interplay with apoptosis network in triple-negative breast cancer.
Şakalar Ç; İzgi K; İskender B; Sezen S; Aksu H; Çakır M; Kurt B; Turan A; Canatan H
Tumour Biol; 2016 Apr; 37(4):4467-77. PubMed ID: 26500095
[TBL] [Abstract][Full Text] [Related]
12. Thymoquinone attenuates proinflammatory responses in lipopolysaccharide-activated mast cells by modulating NF-kappaB nuclear transactivation.
El Gazzar MA; El Mezayen R; Nicolls MR; Dreskin SC
Biochim Biophys Acta; 2007 Apr; 1770(4):556-64. PubMed ID: 17292554
[TBL] [Abstract][Full Text] [Related]
13. Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer.
Wilson AJ; Lalani AS; Wass E; Saskowski J; Khabele D
Gynecol Oncol; 2012 Dec; 127(3):579-86. PubMed ID: 23010348
[TBL] [Abstract][Full Text] [Related]
14. Targeting nuclear factor-kappa B activation pathway by thymoquinone: role in suppression of antiapoptotic gene products and enhancement of apoptosis.
Sethi G; Ahn KS; Aggarwal BB
Mol Cancer Res; 2008 Jun; 6(6):1059-70. PubMed ID: 18567808
[TBL] [Abstract][Full Text] [Related]
15. Salinomycin inhibits Akt/NF-κB and induces apoptosis in cisplatin resistant ovarian cancer cells.
Parajuli B; Lee HG; Kwon SH; Cha SD; Shin SJ; Lee GH; Bae I; Cho CH
Cancer Epidemiol; 2013 Aug; 37(4):512-7. PubMed ID: 23545383
[TBL] [Abstract][Full Text] [Related]
16. Thymoquinone as an anticancer agent: evidence from inhibition of cancer cells viability and invasion in vitro and tumor growth in vivo.
Attoub S; Sperandio O; Raza H; Arafat K; Al-Salam S; Al Sultan MA; Al Safi M; Takahashi T; Adem A
Fundam Clin Pharmacol; 2013 Oct; 27(5):557-69. PubMed ID: 22788741
[TBL] [Abstract][Full Text] [Related]
17. Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, and cisplatin enhances the inhibition of growth of human ovarian cancers.
Yokoyama Y; Xin B; Shigeto T; Mizunuma H
J Cancer Res Clin Oncol; 2011 Aug; 137(8):1219-28. PubMed ID: 21681689
[TBL] [Abstract][Full Text] [Related]
18. Antitumor and anti-angiogenesis effects of thymoquinone on osteosarcoma through the NF-κB pathway.
Peng L; Liu A; Shen Y; Xu HZ; Yang SZ; Ying XZ; Liao W; Liu HX; Lin ZQ; Chen QY; Cheng SW; Shen WD
Oncol Rep; 2013 Feb; 29(2):571-8. PubMed ID: 23232982
[TBL] [Abstract][Full Text] [Related]
19. Thymoquinone attenuates monocrotaline-induced pulmonary artery hypertension via inhibiting pulmonary arterial remodeling in rats.
Zhu N; Zhao X; Xiang Y; Ye S; Huang J; Hu W; Lv L; Zeng C
Int J Cardiol; 2016 Oct; 221():587-96. PubMed ID: 27420584
[TBL] [Abstract][Full Text] [Related]
20. Pronounced transcriptional regulation of apoptotic and TNF-NF-kappa-B signaling genes during the course of thymoquinone mediated apoptosis in HeLa cells.
Sakalar C; Yuruk M; Kaya T; Aytekin M; Kuk S; Canatan H
Mol Cell Biochem; 2013 Nov; 383(1-2):243-51. PubMed ID: 23943306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
